Articles On Race Oncology (ASX:RAC)

Race Oncology (RAC) advanced studies of its cancer-treating drug, Zantrene over the June quarter The drug was found to protect the hearts of mice against the damage caused by certain chemotherapy drugs During the period, the company report...

US FDA approves the first clinical trial using naturally derived psychedelic drugs It could open possibilities for other clinical trials to follow suit Best and worst biotechs over the past month In a ground-breaking development, the US F...

A recent research reveals which biotech segments VCs are ploughing billions of dollars into We list the ASX companies that are operating within those thematics We also list the best and worst ASX biotech performers over the past week and m...

The Race Oncology Ltd (ASX: RAC) share price had yet another stunning day, leaving the broader index well behind. At close of trade, the specialty pharmaceutical company’s shares finished 15.74% ahead at $2.50 each. This means the comp...

ASX renewable energy shares incorporate a range of companies involved in producing clean energy sources. They span several sectors including resources, materials, and energy. Think lithium explorers, battery producers, electric vehicle ma...

ShareCafeEvening Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket closed at session lows and had its worst day in two weeks in a broad-based rout. At the closing bell, the S&P/ASX 200 was almost 2 per cent or 132 p...

A number of ASX shares in the S&P/ASX 200 Health Care Index (ASX: XHJ) outperformed the broader market today. The benchmark S&P/ASX 200 Index (ASX: XJO) backtracked yet again, ending Thursday’s session 1.97% lower at 6,568.1 poin...

ShareCafeLunch Report: 30 June, 2022 by Melissa Darmawan   The Australian sharemarket has fallen for a second day and is on track to have its worst month since March 2020. At noon, the S&P/ASX 200 is 0.8 per cent or 52 points lower at 6...

30 Jun 2022 - A snapshot of the stocks on the move featuring, Paradigm Biopharmaceuticals (ASX:PAR), Estrella Resources (ASX:ESR), and Race Oncology (ASX:RAC).

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated. In our prior dispatch,...

The Cann Group Ltd (ASX: CAN) share price is rocketing on Thursday. This comes after the cannabis company announced a positive update regarding its Mildura facility. At the time of writing, Cann shares are fetching at 27.5 cents, up 19.57%...

Race Oncology (RAC) announces its Zantrene product can protect mice hearts from permanent damage caused by anthracyclines which is an anti-cancer treatment While they’re a highly effective chemotherapy treatment, anthracyclines can cause s...

Cann Group’s Mildura facility has been granted GMP licence Paradigm receives patent application acceptance by IP Australia Starpharma to relaunch VIRALZEE with LloydsPharmacy in the UK Cannabis company Cann Group (ASX:CAN) rose 17% this m...

The Race Oncology Ltd (ASX: RAC) share price is surging today on anti-cancer drug news. Shares in the oncology company reached $2.10 in early trading, a 13% gain. For perspective, the S&P/ASX All Ordinaries Index (ASX: XJO) is 0.87...

Race Oncology (RAC) releases positive final results from a preclinical research program exploring the use of Zantrene with drug combinations to treat melanoma The company reports that when combined with standard of care BRAF and MEK protei...

The Australian share market is home to a good number of shares that have the potential to grow strongly in the future. But is it home to any 20-baggers? A 20-bagger is a share that provides a return 20 times greater than your original inve...

Race Oncology demonstrates positive results in melanoma therapy HITIQ extends deal with NZ Rugby Arovella set to launch in Australia Race Oncology (ASX:RAC)’s study of lead drug Zantrene in cancer immunotherapy has demonstrated positive r...

Interim results from a Race Oncology (RAC) preclinical research program show its Zantrene drug has the potential to enhance immunotherapy outcomes in melanoma Race says the research program has found that used at low concentrations, Zantr...

The Race Oncology Ltd (ASX: RAC) share price flew higher today following a positive announcement by the pharmaceutical company. At Tuesday’s market close, Race Oncology shares ended the day up 9.90% to $1.665. Let’s take a look at what...

ShareCafeEvening Report: 9 June, 2022 by Melissa Darmawan   The Australian sharemarket fell to a four week low pulled down by banks as concerns of rising interest rates and bad debts weighed on investor sentiment. Adding to the fears were n...

Benchmark and small cap index down hard Life on the indices can be hard, unless your in energy, possibly materials Pearl Gull Iron is an island, literally and figuratively   The ASX200 and its emerging companies sidekick have retreated in...

ShareCafeLunch Report: 9 June, 2022 by Melissa Darmawan   The major banks weigh on the Australian sharemarket after the Reserve Bank of Australia announced its outsized interest rate hike this week. Investors are concerned about the impact...

The Race Oncology Ltd (ASX: RAC) share price is surging today after the specialty pharmaceutical company made an announcement regarding an on-market share buyback. At the time of writing, Race Oncology shares are swapping hands at $1.96, u...

09 Jun 2022 - A snapshot of the stocks on the move featuring, Charger Metals (ASX:CHR) and Lithium Australia (ASX:LIT), Race Oncology (ASX:RAC), and Syrah Resources (ASX:SYR).

Race Oncology (RAC) has launched an on-market share buyback program to purchase up to four million RAC shares over the next year The company is aiming to take advantage of market volatility to buy the shares in periods where the price unde...

Highlights Race Oncology expands its clinical trial in EMD AML and MDS across five new sites in Europe The study supports the Pillar 3 FDA registration ambitions and builds on Zantrene’s historical safety and efficacy in AML The clini...

Race Oncology (RAC) is set to expand its BISECT cancer trial for its Zantrene product to include five additional trial sites in Spain and Italy With the extra trial sites, Race has signed a new clinical support agreement with Parexel Inter...

Race Oncology expands its Phase 1b/2a clinical trial of Zantrene to Europe Nova Eye roll out iTrack Advance in select markets in Europe and the Asia Pacific Microba’s autoimmune disease program has officially commenced Race Oncology to ex...

Cancer treatment company Race Oncology (RAC) comes out of a trading halt to announce the completion of the first phase of its Zantrene combination study The study, conducted in Israel, dosed six patients with relapsed acute myeloid leukaem...

Highlights Race Oncology has received encouraging results from the first-stage trial of Zantrene in relapsed or refractory Acute Myeloid Leukaemia. The very heavily pre-treated AML patient population has shown encouraging clinical resp...

Race Oncology completed dosing stage of Phase, eyes Phase 2 trial Immutep presents trials data at ASCO 2022 meeting Clarity Pharma presents at the Jefferies Biotech Summit Race Oncology (ASX:RAC) has completed the dose escalation stage of...

Both ASX Small Cap and benchmark index are down about 0.5% A bleak forecast from Covid-stricken China hits resources stocks Appen in trading halt after jumping 30%     Local markets took a turn for the worse on Thursday after Chinese Prem...

The Race Oncology Ltd (ASX: RAC) share price edged higher before being frozen today. This comes after the pharmaceutical company requested its shares be placed in a trading halt. At the time of writing, Race Oncology shares are on ice at $...

Highlights: Race Oncology is riding high with governance approval for human trial of its new therapy Zantrene®. The cancer drug will be studied in patients with extramedullary Acute Myeloid Leukaemia (AML) or high-risk Myelodysplastic...

Race Oncology (RAC) receives governance approval for a clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Together with ethics approval and completion of site training due to start...

Race Oncology is set to commence Phase 1 study of Zantrene after being given governance approval Rhythm Biosciences has filed blood test ColoSTAT with the TGA Proteomics gets $400k government funding Race Oncology (ASX:RAC) has just recei...

The Healthcare sector has been struggling as the pandemic wanes But most money managers are still bullish on the sector The biggest movements and news from ASX healthcare stocks this week  Dr Anthony Faucci, America’s top infectious disea...

The healthcare sector is experiencing a dry run IPO listings have fallen significantly on weak market appetite  A snapshot of the return of recent ASX Healthcare IPO stocks We are currently in the longest and steepest bear market for biot...

Race Oncology (ASX:RAC) has received human ethics approval for its open-label clinical trial of Zantrene in patients with extramedullary Acute Myeloid Leukaemia or high-risk Myelodysplastic Syndrome.

The ASX200 has taken a 0.5% hit on Wednesday, with the tech sector giving back all the previous session’s gains after Wall Street fell and the tech-laden Nasdaq Composite lost 2.3% overnight. The overnight session was dominated by comments...

Race Oncology (RAC) receives human ethics approval for its clinical trial of Zantrene in patients with acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS) Before patients can be enrolled and treated at the lead site, Race must...

Biotech sector has had a tough time recently But there are signs of things improving this year A look at biotech movers on the ASX in the past fortnight Biotech stocks entered a bear phase in the middle of 2021, and things haven’t improve...

Race Oncology (ASX:RAC) has shared the interim results from the extramedullary acute myeloid leukaemia preclinical program led by cancer researcher, Associate Professor Nikki Verrills.

Race Oncology (RAC) is rapidly advancing its cancer drug as a possible new treatment option for patients with extramedullary acute myeloid leukaemia The news comes after a preclinical program, which found low doses of Zantrene, in combinat...

Race Oncology (ASX:RAC) has shared the final results from the clear cell renal cell carcinoma preclinical program led by eminent cancer researcher, Associate Professor Nikki Verrills of The University of Newcastle and Hunter Medical...

Shares in Race Oncology Ltd (ASX: RAC) are soaring and trading 5% in the green at $2.77 apiece. At one point investors had bid up the share price to $2.99 before it levelled off. The company’s lead drug compound, Zantrene, is back in the...

Race Oncology (RAC) has revealed its Zantrene product can kill a range of kidney cancer cells both on its own and in combination with existing cancer treatments The company recently completed a preclinical program testing the drug on the m...

“Advanced kidney cancer has a large unmet need for improved treatment options and Zantrene in combination with existing treatments may offer new hope for patients with this devastating disease," says chief scientific officer Dr Daniel Tille...

Shares in Race Oncology Ltd (ASX: RAC) soaring today to finish trading 14% higher in the green. The Race Oncology share price flamed higher despite no market-sensitive information from the company’s camp, nor was there any major upsets in...